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ttp://dx.doi.org/10.1016/j.ajpath.2012.11.018Progressive accumulation of a-synuclein (a-syn) in limbic and striatonigral systems is associated with the
neurodegenerative processes in dementia with Lewy bodies (DLB) and Parkinson’s disease (PD). The
murine Thy-1 (mThy1)-a-syn transgenic (tg) model recapitulates aspects of degenerative processes
associated with a-syn accumulation in these disorders. Given that axonal and synaptic pathologies are
important features of DLB and PD, we sought to investigate the extent and characteristics of these
alterations in mThy1-a-syn tg mice and to determine the contribution of a-syn c-terminally cleaved at
amino acid 122 (CT a-syn) to these abnormalities. We generated a novel polyclonal antibody (SYN105)
against the c-terminally truncated sequence (amino acids 121 to 123) of a-syn (CT a-syn) and performed
immunocytochemical and ultrastructural analyses in mThy1-a-syn tg mice. We found abundant clusters of
dystrophic neurites in layers 2 to 3 of the neocortex, the stratum lacunosum, the dentate gyrus, and cornu
ammonis 3 of the hippocampus, striatum, thalamus, midbrain, and pons. Dystrophic neurites displayed
intense immunoreactivity detected with the SYN105 antibody. Double-labeling studies with antibodies to
phosphorylated neuroﬁlaments conﬁrmed the axonal location of full-length and CT a-syn. a-Syn
immunoreactive dystrophic neurites contained numerous electrodense laminated structures. These
results show that neuritic dystrophy is a prominent pathologic feature of the mThy1-a-syn tg model and
suggest that CT a-syn might play an important role in the process of axonal damage in these mice as well
as in DLB and PD. (Am J Pathol 2013, 182: 940e953; http://dx.doi.org/10.1016/j.ajpath.2012.11.018)Supported in part byNIH grants (AG 11385, AG 18840, AG 022074, andNS
044233) and in part by Neotope Biosciences.
TheNIH had no role in the study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
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dementia, and idiopathic PD are common causes of move-
ment impairment and cognitive dysfunction in the ageing
population. Jointly, this heterogeneous group of disorders
often is referred to as Lewy body disease (LBD). A common
feature in LBD is the extensive accumulation of a-synuclein
(a-syn) in cortical and subcortical regions. a-Syn is a 14-kDa
natively unfolded protein, which in the central nervous
system1 is found at the presynaptic terminal,2 where it is
thought to play a role in synaptic plasticity.3
In LBD, a-syn accumulates in multiple cellular compart-
ments including the synaptic terminals,4e6 axons,7 and neu-
ronal cell bodies (Lewy bodies).8e11 Although Lewy bodies
containing ﬁbrillar a-syn are the pathologic hallmark of thestigative Pathology.
.disease, accumulation of other a-syn species in the synapses
and axons has been suggested to be responsible for the im-
pairment of the neural circuitries and neurodegeneration.12e14
Recent work suggests that a-syn oligomers rather than ﬁbrils
might be the neurotoxic species.15e17 C-terminally cleaved
species of a-syn are thought to contribute to this process of
increased oligomerization and toxicity.12,14
Axonopathy and CT-a-Syn in DLB and MiceC-terminally truncated a-syn (CT a-syn) species consis-
tently show a faster ﬁbrillization rate than full-length a-syn.18
In transgenic (tg) mouse brain, C-terminal truncation (CT)
leads to an enhanced pathology in various models of
LBD.19e21 Truncateda-synmay originate from the activity of
proteasomal or lysosomal enzymes,22,23 or may be cleaved by
proteases such as matrix metalloproteinases24e26 or calpain-
1.27,28 Tg a-syn murine models develop numerous functional
deﬁcits that likely relate to the widespread accumulation of
insoluble a-syn in cortical and subcortical circuitries. For
example, murine Thy-1 (mThy1)-a-syn tgmice displaymotor
and nonmotor deﬁcits reminiscent of those observed in DLB
and the premanifest phase of PD.29 These mice also display
neurodegenerative pathology and a-syn accumulation in the
neocortex, hippocampus, basal ganglia, and brainstem, fol-
lowed by a 40% loss of striatal dopamine and L-dopae
responsive motor deﬁcits by 14 to 15 months of age, and
deﬁcits in Morris Water Maze performance.4,30
Given that axonal pathology is an important feature of
LBD, the present study examined the extent and character-
istics of axonal alterations in the mThy1-a-syn tg model and
investigated the contribution of CT a-syn to these abnor-
malities. To this end, we used a novel antibody (SYN105)
generated against a-syn c-terminally cleaved at amino acid
(aa) 122 to perform immunohistochemical and electron
microscopic analyses in mThy1-a-syn tg mice.
Materials and Methods
Transgenic a-Syn Mouse Model
This study was conducted in heterozygous tg mice overex-
pressing human wild-type a-syn under the mThy1 promoter
(mThy1-a-syn of line 61).31 This well-characterized tg
model was selected because of its noted behavioral deﬁcits in
tests of sensory-motor function. The robustness of these be-
havioral deﬁcits is preserved across frequent rounds of
repeated testing.32,33 These mice also display abnormal
accumulation of detergent-insoluble a-syn and develop
a-syneimmunoreactive inclusion-like structures in the brain.
Although some nuclear staining has been observed in this
model, other distinct cytoplasmic inclusion-like structures
consistently have been identiﬁed by confocal and electron
microscopy.31,34 The mThy1-a-syn tg mice were created and
were maintained on a hybrid C57BL/6-DBA/2 back-
ground.31 Animals were kept on this background by mating
N5 females hemizygous for the transgene with male wild-
type mice on the hybrid background obtained from Charles
River Laboratories, Inc. (Wilmington, MA).32,33 The mice
used for this study were 6-month-old female mThy1-a-syn tg
mice (n Z 8), a-syn knockout mice (n Z 8; ID: 003692;
Jackson Laboratories, Bar Harbor, ME), and non-tg mice (n
Z 8). Additional control experiments were conducted with
6-month-old male (nZ 5) and female (nZ 5) mThy1-a-syn
tg mice to evaluate gender differences in a-syn detection with
the SYN105 antibody.The American Journal of Pathology - ajp.amjpathol.orgHuman Specimens and Neuropathology
A total of 10 cases (nZ 5 non-demented controls and nZ 5
DLB) were included for the present study. Autopsy material
was obtained from patients studied neurologically and
psychometrically at the Alzheimer Disease Research Center/
University of California, SanDiego. The last neurobehavioral
evaluation was performed within 12 months before death and
included the Blessed score, Mini Mental State Examination,
and dementia-rating scale.35,36 The demographics of the
samples used are presented in Table 1.
Brains were processed and evaluated according to stan-
dard methods.37 At autopsy, brains were divided sagittally
and the left hemibrain was ﬁxed in formalin with 4%
paraformaldehyde for neuropathologic analysis and the right
hemibrain was frozen at 70C for subsequent neuro-
chemical analysis. Parafﬁn sections from 10% buffered
formalin-ﬁxed, neocortical, limbic system, and subcortical
material stained with H&E, thioﬂavine-S, ubiquitin (Dako,
Carpinteria, CA), and a-syn (Millipore, Temecula, CA)
were used for routine neuropathologic analysis that included
assessment of plaques, tangles, Lewy bodies, and Braak
stage.37 The diagnosis of DLB was based on the initial
clinical presentation with dementia followed by parkin-
sonism and the presence of a-syn and ubiquitin-positive
Lewy bodies in cortical and subcortical regions.38,39
For human brains, sections from the putamen and hippo-
campus were used. Sections were incubated at 4C overnight
with the polyclonal antibodies against a-syn (Millipore)
and CT a-syn (SYN105). Sections then were incubated in
secondary antibody (1:75; Vector Laboratories, Inc., Bur-
lingame, CA), followed by avidin Dehorseradish peroxidase
(ABC Elite; Vector Laboratories, Inc.) and reacted with
diaminobenzidine (0.2 mg/mL) in 50 mmol/L Tris (pH 7.4)
with 0.001% H2O2.
Generation and Characterization of the Rabbit SYN105
Antibody Against CT a-Syn
An immunogenic peptidewith the sequence of CGGVDPDN,
in which CGG are artiﬁcial aa added for conjugation and
spacing and VDPDN are aa 118 to 122 of a-syn, was
synthesized by Anaspec (San Jose, CA). This peptide was
conjugated to Imject Maleimide Activated cationized bovine
serum albumine (cBSA) from Pierce (Rockford, IL)
following the manufacturer’s protocol. The complete immu-
nogen was supplied to Josman Labs (Napa, CA), who
immunized rabbits following a modiﬁcation of their standard
protocol. Bleeds were collected monthly starting at week 7.
Once a sufﬁcient titer to the immunizing peptide was ob-
tained, the antibody was puriﬁed on an afﬁnity column
prepared by coupling the immunizing peptide to SulfoLink
Coupling Resin (Pierce) following the manufacturer’s
protocol.
The antibody was characterized by both selective binding to
a-syn truncated at aa 122 versus full-length a-syn and by941
Table 1 Demographic Details of Human Samples Used
Diagnosis N Z Age, years
Disease duration,
years Sex, M/F
Blessed
score range Brain weight Braak stage
Non-demented control 5 84  4 NA 3/2 0e1 1320  98 0eI
Dementia with Lewy bodies 5 79  5 10  3 3/2 20e33 1125  174 IVeV
F, female; M, male; NA, not applicable.
Games et alepitope mapping on overlapping 10-mer peptides. The
comparative binding enzyme-linked immunosorbent assay
(ELISA) was conducted by coating a plate with either puri-
ﬁed full-length a-syn or truncated a-syn at 10 mg/mL. Plates
were blocked, aspirated, and dilutions of the SYN105 anti-
body were incubated on the plates for 2 hours followed by
washing. The plates then were incubated in goat anti-rabbit
horseradish peroxidase for 1 hour and washed. Plates were
developed using o-phenylenediamine dihydrochloride with
an acid stop, and then read at 490 nm. The shift in 50%
binding was determined to give a relative shift in afﬁnity and
we found that SYN105 had a 20-fold preference for a-syn
truncated at aa 122.
For epitope screening, 10 aa peptides were synthesized at
Biopeptide, Co., Inc. (San Diego, CA) with N-terminally
added biotins encompassing aa 106 to 128 with a nine aa
overlap. The peptides were bound to a Pierce neutravidin
plate and a 10 mg/mL antibody solution was incubated with
the peptides for 1 hour. Plates were washed and incubated for
1 hour with goat anti-rabbit IgGehorseradish peroxidase.
Plates were washed and then developed with OPD, with an
acid stop, and read at 490 nm.
Immunoblot Analysis
Brieﬂy, as previously described, samples from the hippo-
campus and caudate putamen of mThy1-a-syn tg mice, non-
tg mice, a-syn knockout controls, and DLB patients were
homogenized and divided into Tris-buffered saline (TBS)-
cytosolic, Triton X-100-membrane, and urea-insoluble
fractions.19,40 For immunoblot analysis, 20 mg of TBS-
soluble protein per lane was loaded into 4% to 12% Bis-Tris
[Bis(2-hydroxyethyl) aminotris (hydroxymethyl) methane]
SDS-PAGE (denaturing or on native/nondenaturating) gels
and blotted onto nitrocellulose membranes. To charac-
terize the SYN105 antibody, membranes were incubated
with either SYN105 (1:1000, rabbit polyclonal antibody
against a-syn c-terminally truncated at aa 122) or against
full-length a-syn [1:1000, full-length (FL) a-syn rabbit
polyclonal; Millipore]. Incubation with primary antibodies
was followed by species-appropriate incubation with
secondary antibodies tagged with horseradish peroxidase
(1:5000; Santa Cruz Biotechnology, Santa Cruz, CA),
visualization with enhanced chemiluminescence, and
analysis with a Versadoc XL imaging apparatus (BioRad,
Hercules, CA). Analysis of b-actin (1:1000; Sigma, St.
Louis, MO) or tubulin (1:1000, b-tubulin; Chemicon,
Temecula, CA) levels was used as a loading control.942Mass Spectrometry
Recombinant a-syn ( calpain-1 treatment) (30 mg) was
electrophoresed on a 4% to 12% Bis-Tris gel, blotted for
a short period (10 minutes, 30 volt) onto a PVDF membrane,
and stained with the SYN105 antibody as described earlier.
After transfer, the gel was rinsed with water and stained with
the SilverQuest Staining Kit (Invitrogen Life Technologies,
Carlsbad, CA), imaged, and sliced horizontally. Gel slices
were de-stained, rinsed, and consecutively digested with
sequencing-grade trypsin as previously described.41 Trypsin-
digested peptides were analyzed by high-pressure liquid
chromatography coupled with tandem mass spectroscopy
using nanospray ionization. The nanospray ionization
experiments were performed using a Triple-time-of-ﬂight
5600 mass spectrometer (MS) (AB SCIEX, Framingham,
MA), interfaced with nano-scale reversed-phase high-pressure
liquid chromatography [Tempo (2,2,6,6-tetramethyl-1-piper-
idinyloxy)], using a 10-cme100-micron internal diameter
glass capillary packed with 5-mm C18 Zorbax beads (Agilent
Technologies, Santa Clara, CA). Peptides were eluted from
the C18 column into the mass spectrometer using a linear
gradient (5% to 60%) of acetonitrile at a ﬂow rate of 250 mL/
min for 1 hour. The buffers used to create the acetonitrile
gradient were as follows: buffer A [98% H2O, 2% acetoni-
trile, 0.2% formic acid, and 0.005% trifuoroacetic acid
(TFA)] and buffer B (100% acetonitrile, 0.2% formic acid,
and 0.005% (TFA). Tandem mass spectrometry data were
acquired in a data-dependent manner in which the MS1 data
were acquired for 250 ms at a mass to charge ratio of 400 to
1250 Da and the MS/MS tandem mass spectrometry data
were acquired from a mass to charge ratio of 50 to 2000 Da.
For independent data acquisition the following parameters
were used: a 250 ms time of ﬂight survey scan (MS1-TOF)
was followed by a 50 product ion scan (MS2) of 25 ms each.
For MS2 criteria, ions that had reached the treshold of 200
counts and the charge state of þ2,þ3 or þ4 were selected
and a four second exclusion criteria was chosen to limit the
number of MS2 repetitive elements on the same ion. Finally,
the collected data were analyzed using ProteinPilot 4.0
(ABSCIEX) for peptide identiﬁcations.
Immunocytochemical and Neuropathologic Analyses
Analysis of a-syn accumulation was performed in serially
sectioned, free-ﬂoating, blind-coded 40-mm vibratome sec-
tions by incubating the sections overnight at 4Cwith either the
SYN105 (1:500, rabbit polyclonal antibody against a-synajp.amjpathol.org - The American Journal of Pathology
Axonopathy and CT-a-Syn in DLB and Micec-terminally truncated at aa 122), a polyclonal antibody against
full-length a-syn (1:500; Millipore),42 an antibody against
pathologic a-syn found in Lewy bodies [1:500, mouse
monoclonal (LB 509); Abcam, Cambridge,MA], or against a-
syn phosphorylated at serine 129 [1:500, rabbit polyclonal;
(pSer129) Millipore]. Incubation with primary antibodies was
followed by incubation with species-appropriate secondary
antibodies including biotinylated goat anti-rabbit IgG1 (1:100;
Vector Laboratories, Inc.), avidin Dehorseradish peroxidase
(1:200, ABC Elite; Vector Laboratories, Inc.), and, ﬁnally,
detection with diaminobenzidine. Sections were analyzed
using an Olympus BX-41 upright pathology microscope
(Olympus America Inc., Center Valley, PA).
Double Immunolabeling and Fluorescence Co-labeling
To determine the co-localization betweena-synwith different
antibodies and with other cellular markers, double-labeling
experiments were performed, as previously described.43 For
this purpose, vibratome sections were immunolabeled with
the mouse monoclonal antibodies against human a-syn
(SYN211, 1:500; Santa Cruz Biotechnology) and the rabbit
polyclonal CT a-syn (SYN105). Sections also were double-
labeled with SYN105 and mouse monoclonal antibodies
against the synaptic vesicle marker, synaptophysin (1:500;
Abcam), the axonal phosphorylated low-molecular-weight
neuroﬁlaments (SMI312, 1:500; Abcam), the dendritic
microtubule-associated protein-2 (1:100; Millipore), or glial
ﬁbrillary acidic protein (1:500; Millipore). The CT a-syn
immunoreactive structures were detected with the Tyramide
Signal Ampliﬁcation-Direct (Red) system (1:100; NEN Life
Sciences, Boston, MA); whereas SYN211, SMI312, and
microtubule-associated protein-2 were detected with ﬂuo-
rescein isothiocyanateetagged antibodies (1:75; Vector
Laboratories, Inc.). All sections were processed simulta-
neously under the same conditions and experiments were
performed in triplicate to assess the reproducibility of results.
Sections were imaged with a Zeiss (Oberkochen, Germany)
high magniﬁcation (63) objective (numerical aperture, 1.4)
on an Axiovert 35 microscope (Zeiss) with an attached
MRC1024 laser scanning confocal microscope system (Bio-
Rad).42 A series of 10 Z optical sections were acquired at an
average depth of 2 mm and were used to estimate the
proportion of SYN105-immunoreactive neurites that co-
localized with synaptophysin.
Electron Microscopy and Immunogold Analysis
Brieﬂy, vibratome sections were postﬁxed in 1% glutaralde-
hyde, treated with osmium tetraoxide, embedded in epon aral-
dite, and sectioned with the ultramicrotome (Leica, Nussloch,
Germany). Grids were analyzed with a Zeiss OM 10 electron
microscope as previously described.44 For immunogold
labeling, sections were mounted in nickel grids, etched, and
incubatedwith theSYN105antibody, followedby labelingwith
10-nm Aurion ImmunoGold particles (1:50; ElectronThe American Journal of Pathology - ajp.amjpathol.orgMicroscopy Sciences, Fort Washington, PA) with silver
enhancement. Electron micrographs were obtained at a magni-
ﬁcation of25,000.
Results
The Polyclonal Antibody SYN105 Preferentially
Recognizes C-TerminaleTruncated a-Syn
To investigate the biochemical properties and axonal dis-
tribution patterns of CT a-syn in mThy1-a-syn tg mice and
human tissue, we generated a novel antibody, SYN105. The
SYN105 antibody was raised to recognize a major calpain-1
cleavage site (amino acid 122) of human a-syn28 (Figure 1A).
By ELISA, the antibody had a 20-fold preference for aa
122etruncated a-syn (Figure 1B). Epitope mapping showed
that the SYN105 antibody bound preferentially to peptides
ending at aa 121, aa 122, and aa 123 (Figure 1C). There was no
reaction to a peptide ending at aa 125 even though it contained
the entire immunogen sequence (Figure 1C).
Next, we tested the speciﬁcity of the SYN105 antibody
in brain homogenates. For this purpose, TBS-soluble frac-
tions of caudate putamen or hippocampi from 6-month-old
mThy1-a-syn tg mice, non-tg, and a-syn knockout controls
were analyzed and compared with striatal and hippocampal
samples from DLB cases. These samples initially were
analyzed with the SYN105 antibody, which robustly detec-
ted both the 14-kDa and 12-kDa species of a-syn in the
mThy1-a-syn tg mice and in the DLB samples. The 12-kDa
fragment of a-syn was detected at around equal levels to
monomeric a-syn and was strongly visible in caudate puta-
men and to a minor extent in the hippocampi of mThy1-a-
syn tg mice (Figure 1D). The 12-kDa fragment of a-syn was
detected prominently in the caudate putamen and hippo-
campal samples from the DLB cases (Figure 1D).
In contrast, immunoblot with an antibody against FL a-syn
(Figure 1D) (aa 91 to 99), showed predominant detection of
monomeric mouse and human a-syn (14 kDa) in the caudate
putamen and hippocampus of mThy1-a-syn tg mice and in
the human samples. An additional minor signal of human
a-syn was detected at a lower molecular weight (12 kDa,
Figure 1D). This lower band was not seen in protein extracts
from non-tg mice using the FL a-syn antibody or other anti-
bodies against the CT of a-syn (aa 121 to 125; SYN211; data
not shown).
To evaluate the speciﬁc of SYN105 to a-syn oligomers,
TBS-soluble fractions of caudate putamen or hippocampi
from mThy1-a-syn tg mice and non-tg controls were run on
a nondenaturing native gel (Figure 1E). SYN105 detected
higher-molecular-weight a-syn species in samples from the
caudate putamen or hippocampus of mThy1-a-syn tg mice
(Figure 1E). No signal was observed in the samples from
non-tg mice.
To further investigate and corroborate the speciﬁcity of the
SYN105 antibody to calpain-cleaved a-syn, recombinant
a-syn incubated with calpain-1 for 0, 10, and 60 minutes943
Figure 1 Characterization of the novel CT a-syn antibody SYN105. A: Schematic diagram of the a-syn peptide indicating epitopes relevant to the
antibodies used in this study. B: ELISA analysis of the relative speciﬁcities of the SYN105 antibody for FL a-syn and a-syn truncated at amino acid (aa) residue
122. C: Epitope-mapping of puriﬁed SYN105 with 10-mer overlapping peptides. D: Immunoblot analysis on a denaturing SDS-PAGE gel with the SYN105
antibody and the FL a-syn antibody of TBS-soluble protein extracts from the caudate putamen (CPu) and hippocampal (HPc) regions of 6-month-old non-tg
mice, a-syn knock-out mice, mThy1-a-syn tg, and control and DLB human samples. E: Immunoblot analysis on a native (nondenaturing) PAGE gel with the
SYN105 antibody of TBS-soluble protein extracts from the CPu and hippocampus (HPc) regions of 6-month-old non-tg (co) and mThy1-a-syn tg (tg). F:
Samples from recombinant a-syn incubated with calpain-1 for 0, 10, and 60 minutes, and with recombinant a-syn incubated with calpain-1 þ calpeptin
(inhibitor, I), analyzed with the SYN105 antibody. G: Recombinant a-syn was subjected to gel electrophoresis and short blotting before silver staining to
document slice sides corresponding to SYN105 immunoreactivity of CT a-syn. Gel slices between 10 and 12 kDa were excised (red asterisk). H: Tryptic peptides
(black asterisks) of liquid chromatography coupled with tandem mass spectrometry spectra were analyzed using Mascot (Matrix Science, London, UK) and
detected peptides (in bold) corresponding to a-syn spanning aa 13 to 122.
Games et alwas analyzed by immunoblot. Recombinant a-syn also was
incubated with calpain-1 in the presence of calpeptin, an
inhibitor (I, Figure 1F) of calpain. Immunoblot analysis of
recombinant a-syn incubated with calpain-1 for 10 minutes
with the SYN105 antibody detected a band at 12 kDa repre-
senting the calpain-1 cleavage product. This band was more
prominent after 60 minutes of incubation, as was a much
higher molecular weight band (Figure 1G). SYN105 only
detected the FL a-syn when recombinant a-syn was incubated
with calpain in the presence of calpeptin (Figure 1F).
To further characterize the speciﬁcity of the SYN105
antibody for CT a-syn bands co-migrating with calpain-
cleaved recombinant a-syn as identiﬁed by immunoblotting
using SYN105 and silver staining (Figure 1G), signals were
analyzed by reverse-phase chromatography. Peaks were944collected and peptide masses were determined by sequencing
of tryptic peptides using liquid chromatography coupled with
tandem mass spectroscopy. This analysis detected peptides
corresponding to a-syn spanning aa 13 to 122 (Figure 1H).
Collectively, these results show that the SYN105 anti-
body has a high afﬁnity for calpain-cleaved CT a-syn and
suggest that CT a-syn truncation may be a speciﬁc char-
acteristic of human a-syn.
The mThy1-a-Syn Tg Mice Display Extensive
Accumulation of SYN105-Reactive CT a-Syn in
Dystrophic Neurites
Immunohistochemical analysis with the SYN105 antibody
against CT a-syn showed strong immunolabeling of theajp.amjpathol.org - The American Journal of Pathology
Figure 2 Immunohistochemical characterization of the SYN105 CTa-syn.A: Low-magniﬁcation image of immunoreactivity in a representativemThy1-a-syn tg
mouse using the SYN105 antibody. B: Representative high-magniﬁcation images of SYN105 signal in the frontal cortex and molecular layer (ML) of the dentate
gyrus (DG), stratum lacunosum, and cornu ammonis 1 (CA1) regions of the hippocampus (hip) of mThy1-a-syn tg mice. Arrows indicate dystrophic neuritis
containing alpha-synuclein accumulation. C: Representative high-magniﬁcation images of SYN105 signal in the basal ganglia, thalamus, substantia nigra
(s. nigra), and cerebellum of mThy1-a-syn tg mice. Insets are presented at higher magniﬁcation in the lower panels. D: Low-magniﬁcation image of immuno-
reactivity in a representativemThy1-a-syn tgmouse using the FLa-syn antibody. E: Representative high-magniﬁcation images of FLa-syn immunoreactivity in the
frontal cortex and molecular layer (ML) of the dentate gyrus (DG), stratum lacunosum, and CA1 regions of the hippocampus of mThy1-a-syn tg mice. F: Repre-
sentative high-magniﬁcation images of FL a-syn immunoreactivity in the basal ganglia, thalamus, substantia nigra, and cerebellum of mThy1-a-syn tg mice.
Arrows indicate dystrophic neuritis containing alpha-synuclein accumulation. Scale bars: 30 mm (B); 40 mm (E).
Axonopathy and CT-a-Syn in DLB and Miceneuropil, throughout cortical and subcortical regions of the
mThy1-a-syn tg mice (Figure 2A). A more detailed analysis
showed that the SYN105 antibody immunostained punctuate-
like structures, varying in size between 1 and 4 mmdiameter in
the neocortical neuropil. The larger dot-like structures were
arranged in clusters and had the appearance of dystrophic
neurites (Figure 2B). In contrast to antibodies recognizing FL
a-syn, only minimal labeling of neuronal cell bodies was
detected. In hippocampal regions, the SYN105 antibody
immunolabeled abundant dot-like structures averaging 1 to 2The American Journal of Pathology - ajp.amjpathol.orgmicrons in diameter, distributed throughout the cornu
ammonis 1 (CA1) and dentate gyrus neuropil (Figure 2B). In
addition, in the molecular layer of the dentate gyrus and in the
stratum lacunosum, the SYN105 antibody immunostained
dystrophic neurites arranged in clusters (Figure 2B). Similar
structures were detected in the neuropil of the basal ganglia,
thalamus, and substantia nigra (Figure 2C). In the cerebellum,
immunostaining was present in punctate structures in both the
molecular and granular cell layers (Figure 2, A and C). The
patterns of immunostaining with the SYN105 antibody were945
Figure 3 Comparative immunostaining pattern in male and female mThy1-a-syn tg mice. A: Immunoblot of a-syn levels in brain samples from 6-month-old
male and female mThy1-a-syn tg mice and non-tg mice using the SYN105 antibody and the FL a-syn antibody. B: Analysis (means  SEM) of a-syn levels in
mThy1-a-syn tg mice and non-tg mice using the SYN105 antibody. C: Analysis (means  SEM) of a-syn levels in mThy1-a-syn tg mice and non-tg mice using
the FL a-syn antibody. D: Immunohistochemical analysis of SYN105 and FL a-syn immunoreactivity in the neocortex of 6-month-old male and female mThy1-a-
syn tg mice. E: Immunohistochemical analysis of SYN105 and FL a-syn immunoreactivity in the basal ganglia of 6-month-old male and female mThy1-a-syn tg
mice. F: Immunohistochemical analysis of SYN105 and FL a-syn immunoreactivity in the substantia nigra (s. nigra) of 6-month-old male and female mThy1-
a-syn tg mice. *P < 0.05 between male and female mice. Scale bars: 30 mm (DeF).
Games et alcompared with those obtained with an antibody that recog-
nizes FLa-syn. This antibody displayed extensive puncta-like
immunolabeling of the neuropil in neocortical, limbic, striatal,
and subcortical regions (Figure 2D). At higher magniﬁcation,
in the neocortex, hippocampus, basal ganglia, and substantia
nigra, the antibody against FL a-syn immunostained neuronal
cell bodies as well as dystrophic neurites (Figure 2, E and F).
However, the dystrophic neurites were immunolabeled more
prominently with the SYN105 antibody.
To evaluate gender differences in SYN105 immunoreac-
tivity, the TBS-soluble fractions from frontal cortex homoge-
nates of 6-month-old male and female mThy1-a-syn tg mice
and both male and female non-tg mice were analyzed. Immu-
noblot with the SYN105 antibody strongly detected a-syn
bands at both14and12kDa, and at highermolecularweights in
both male and female mThy1-a-syn tg mice (Figure 3A). The
14- and 12-kDa bandsweremore prominent inmalemThy1-a-
syn tg mice in comparison with female mThy1-a-syn tg mice946(Figure 3,A andB). SYN105 did not detect speciﬁc bands at 14
or 12 kDa or higher in the non-tg mice (Figure 3A). Immu-
noblot with an antibody against FL a-syn strongly detected a-
syn bands at 14 kDawith onlyminimal detection at 12 kDa and
at highermolecularweights in bothmale and femalemThy1-a-
syn tgmice (Figure 3A). Similar to SYN105, immunoblot with
the antibody against FL a-syn showed that the 14-kDa band
was signiﬁcantly more prominent in male mThy1-a-syn tg
mice in comparison with female mThy1-a-syn tg mice
(Figure 3, A and C). The antibody against FL a-syn did not
detect speciﬁc bands at 14 or 12 kDa or higher in the non-tg
mice (Figure 3A). Immunohistochemical analysis of a-syn
expression in both male and female mThy1-a-syn tg mice in
the neocortex (Figure 3D), basal ganglia (Figure 3E), and
substantia nigra (Figure 3F) using the SYN105 antibody
detected synapses and neurites. Likewise, male and female
mThy1-a-syn tg mice displayed similar patterns of immuno-
reactivity in the brain regions examined (Figure 3, DeF).ajp.amjpathol.org - The American Journal of Pathology
Figure 4 Comparative analysis of a-syn immunoreactivity between mThy1-a-syn tg mice and human DLB using varied antibodies. A: Representative image
of a-syn immunoreactivity in the putamen of a DLB case and a mThy1-a-syn tg mouse immunostained with antibodies against CT a-syn (SYN105), a-syn found
in Lewy bodies (LB509), a-syn phosphorylated at serine 129 (pSer129), and FL a-syn. B: Representative image of a-syn immunoreactivity in the hippocampus
of a DLB case and a mThy1-a-syn tg mouse immunostained with antibodies against CT a-syn (SYN105), a-syn found in Lewy bodies (LB509), a-syn phos-
phorylated at serine 129 (pSer129), and FL a-syn. Scale bar Z 50 mm.
Axonopathy and CT-a-Syn in DLB and MiceComparative Analysis of Mouse and Human Tissue with
SYN105 and Other Common a-Syn Antibodies
To comparatively evaluate the pattern of immunoreactivity
observed with SYN105 to other antibodies against patho-
logic forms of a-syn found in Lewy bodies (as detected by
LB509), phosphorylated a-syn (as detected by an antibody
against pSer129) and FL a-syn sections from the putamen
(Figure 4A) and hippocampus (Figure 4B) from DLB cases
and mThy1-a-syn tg mice were examined.
Immunohistochemical analysis with SYN105 in the puta-
men in DLB and tg mice showed the presence of abundant
punctate-like structures corresponding to dystrophic neurites
(Figure 4A). With the LB509 and pSer129 antibodies, similar
dystrophic neurites were immunostained in the putamen of the
DLB cases and tg mice (Figure 4A). In contrast, the antibody
against full-length a-syn reacted with the neuropil and only
detected very few of the dystrophic neurites (Figure 4A), these
structures had an average diameter of 2 to 4 microns, whereas
the smaller punctae associated with presynaptic boutons mea-
sure an average of 1 micron in diameter.
Immunohistochemical analysis with SYN105 in the
hippocampus of the DLB cases and in tg mice showed theThe American Journal of Pathology - ajp.amjpathol.orgpresence of abundant fusiform and punctate-like structures
(Figure 4B). The LB509 and pSer129 antibodies detected
similar dystrophic neurites in the hippocampus of the DLB
cases and tg mice (Figure 4B). The antibody against FL
a-syn reacted with the neuropil and only detected sparse
dystrophic neurites (Figure 4B).
These results show that the immunoreactivity pattern
observed with the SYN105 antibody is comparable with that
observed with other antibodies aimed at pathologic forms of
a-syn such as the LB509 and pSer129 antibodies.
Co-localization of CT a-Syn with Axonal Markers in the
mThy1-a-Syn Tg
Double-labeling studies with a monoclonal antibody against
human a-syn (SYN211) and SYN105 in the neocortex
(Figure 5A), basal ganglia (Figure 5B), CA1 (Figure 5C),
and stratum lacunosum (Figure 5D) regions of the hippo-
campus showed extensive co-localization in dystrophic
neurites but with only minimal co-localization in neuronal
cell bodies.
No immunostaining with the SYN105 antibody was
observed in sections from non-tg and a-syn knockout mice947
Figure 5 Double-labeling characterization of dystrophic neurites in
mThy1-a-syn tg mice with the SYN105 antibody. Co-localization of
dystrophic neurites with human a-syn detected with the SYN211 antibody
and the SYN105 antibody in the neocortex (A), basal ganglia (B), CA1 (C),
and stratum lacunosum (S. Lacunosum) (D) of the hippocampus in mThy1-
a-syn tg mice with. B. ganglia, basal ganglia. Scale bar Z 20 mm.
Figure 6 Double-labeling characterization of presynaptic and axonal
speciﬁcity of the SYN105 antibody in mThy1-a-syn tg mice. Arrows indi-
cate co-localization of SYN105 immunoreactivity with the presynaptic
marker, synaptophysin, in the neocortex (A), hippocampus (B), basal
ganglia (C), and thalamus (D) of mThy1-a-syn tg mice. Arrows indicate co-
localization of SYN105 immunoreactivity with the axonal neuroﬁlament
marker SMI312 in the neocortex (E), hippocampus (F), basal ganglia (G),
and thalamus (H) of mThy1-a-syn tg mice. Scale bar Z 20 mm.
Games et al(data not shown). Control experiments in which sections
from the mThy1-a-syn tg mice were incubated with
SYN105 that had been pre-adsorbed with a 20-fold excess
of CT a-syn peptide showed a complete abolition of im-
munostaining (data not shown).
To further corroborate the neuronal localization of the CT
a-syn fragments in the mThy1-a-syn tg mice, double-
labeling studies were performed with axonal and dendritic
markers. In the neocortex and hippocampus, approximately
50% of the ﬁner SYN105-positive dot-like structures co-
localized with an antibody against the presynaptic marker
synaptophysin (Figure 6, A and B). Moreover, 35% of the
larger SYN105-positive dystrophic neurites displayed syn-
aptophysin immunoreactivity (Figure 6, A and B). In the
basal ganglia and thalamus, more than 50% of the SYN105-
immunoreactive dystrophic neurites displayed synaptophy-
sin immunoreactivity (Figure 6, C and D). Similarly, analysis
with an antibody against phosphorylated neuroﬁlaments
(SMI312, axonal marker) showed that the SYN105-positive
dystrophic neurites in the neocortex, hippocampus, and
basal ganglia displayed SMI312 immunoreactivity (Figure 6,
EeH). In contrast, there was only minimal co-localization
between SYN105-positive dystrophic neurites and an anti-
body against the dendritic marker microtubule-associated948 ajp.amjpathol.org - The American Journal of Pathology
Figure 7 Double-labeling characterization of speciﬁcity of the SYN105
antibody in mThy1-a-syn tg mice. Co-localization of the dendritic marker,
microtubule-associated protein-2 (MAP2), with SYN105 immunoreactivity
in the neocortex (A), hippocampus (B), basal ganglia (C), and thalamus (D)
of mThy1-a-syn tg mice. Co-localization of glial ﬁbrillary acidic protein
(GFAP) immunoreactivity with SYN105 immunoreactivity in the neocortex
(E), hippocampus (F), basal ganglia (G), and thalamus (H) of mThy1-a-syn
tg mice. Scale bars: 10 mm (AeD); 10 mm (EeH).
Axonopathy and CT-a-Syn in DLB and Mice
The American Journal of Pathology - ajp.amjpathol.orgprotein-2 or glial ﬁbrillary acidic protein in any of the regions
examined (Figure 7).
Consistent with studies in the mThy1-a-syn tg mice, co-
localization studies in hippocampal samples from DLB
cases showed co-localization between SYN105 and syn-
aptophysin and phosphorylated neuroﬁlaments (SMI312,
axonal marker) (Figure 8, A and B) but no co-localization
with glial ﬁbrillary acidic protein (Figure 8C). Taken
together, these results support the notion that the dystrophic
neurites that accumulate CT a-syn epitopes are axonal in
origin.
Ultrastructural Characteristics of the Dystrophic
Neurites in the mThy1-a-syn Tg
To further investigate the subcellular characteristics of the
dystrophic neurites immunostained by SYN105, electron
microscopy (Figure 9, A and B) and immunogold analysis
(Figure 9, C and D) was performed. Transmitted electron
microscopy analysis of sections from the neocortex, hippo-
campus, and basal ganglia of mThy1-a-syn tg mice stained
with uranyl acetate showed typical dystrophic neurites be-
tween 5 and 10mm in diameter displaying abundant laminated
and electrodense bodies (Figure 9B). Immunoelectron
microscopy with the SYN105 antibody showed abundantFigure 8 Double-labeling characterization of speciﬁcity of the SYN105
antibody in DLB. Co-localization of SYN105 immunoreactivity with the
presynaptic marker synaptophysin (A), the axonal neuroﬁlament marker
SMI312 (B), and glial ﬁbrillary acidic protein (GFAP) immunoreactivity (C) in
the hippocampus of a DLB patient. Arrowheads in A indicate dystrophic
neurites that are co-labeled with alpha-synuclein and synaptophysin.
Arrowheads in B indicate axons co-labeled with alpha-synuclein and
phosphorylated neuroﬁlaments.Arrows in C are GFAP positive astroglial cells
and arrowheads are alpha-synculein positive axons. Scale barZ 10 mm.
949
Figure 9 Ultrastructural and immunoelectron
characterization of dystrophic neurites and SYN105
immunoreactivity in the mThy1-a-syn tg mice.
Ultrastructural analysis of neurite morphology
in the neocortex of non-tg mice (A) and the
neocortex, basal ganglia, and hippocampus from
mThy1-a-syn tg mice (B). Immunogold labeling of
membranes of the multilaminated bodies and
electrodense bodies in the neocortex of non-tg
mice (C) and the neocortex, basal ganglia, and
hippocampus of mThy1-a-syn tg mice (D). B.
ganglia, basal ganglia. Original magniﬁcation,
25,000. Scale barZ 1 mm.
Games et algold particles in association with the membranes of the mul-
tilaminated bodies and in the electrodense bodies (Figure 9D).
Discussion
The present study showed that neuritic dystrophy, similar to
that observed in patients with DLB and PD, is a prominent
feature of the mThy1-a-syn tg model and that these
dystrophic neurites accumulate CT a-syn that can be best
detected with the novel SYN105 polyclonal antibody.
Neuritic dystrophy in the hippocampus, basal ganglia, and
subcortical nuclei has been described previously in DLB
and PD dementia patients,7,11,45,46 and PD,47,48 suggesting
that axonal damage might better correlate behavioral and
neurodegenerative pathology than the formation of Lewy
bodies. In addition, in DLB brains, the presynaptic presence
of a-syn aggregates resulted in signiﬁcant synaptic pa-
thology, with reduction of postsynaptic marker expression
and loss of dendritic spines within postsynaptic areas.49
In vitro studies have reported a negative impact of a-syn
on neurite outgrowth and synaptic integration.50 In mouse
embryonic stem cells and in a rat neuronal cell line, lenti
viral overexpression of a-syn resulted in decreased neurite
length and less branching.50,51 Decreased neurite length also
was observed in newly generated, double-cortinepositive
neuroblasts in the dentate gyrus.52 Thus, identiﬁcation of
axonal pathology using in vivo experimental animal models
and in patients with DLB or PD represents both an impor-
tant target and a biomarker for the disease.
Although it is now recognized that abnormal accumulation
of a-syn in synapses and axons (rather than Lewy bodies)
plays a critical role in the pathogenesis of DLB and PD, the
mechanisms leading to this axonal pathology are less clear. In
this study we show that a unique feature of the axonal
pathology in the mThy1-a-syn tg is the presence of abundant
CT-cleaved a-syn as detected with the SYN105 antibody. CT
truncation of a-syn has emerged as a key posttranslational
mechanism that regulates the aggregation capacity of
a-syn.18,22,28,53 Generation of tg animals carrying a CT
deletion of the human construct ranging from aa 1 to 119,21950aa 1 to 120,19 and aa 1 to 13020 induced pathologic alter-
ations speciﬁcally in dopaminergic neurons. In PD and DLB,
levels of calpain-1 are increased in the substantia nigra and
locus coeruleus of PD patients.54 Recent studies have indi-
cated that calpain-1 is responsible for the cleavage of a-syn at
the CT site (aa 122), resulting in the formation of toxic
fragments.12,22,28,55
Moreover, it has been shown that excitotoxicity56,57 and
oxidative stress,58,59 events commonly seen in PD and DLB
patients, might be related to increased calcium levels,59
which in turn can activate calpain-1, resulting in cleavage
of a-syn at the aa 122 of the C-terminus. Consistently, we
recently reported that neuronal accumulation of a-syn is
associated with alterations in calcium-buffering capacity in
our tg mice.60 The resulting fragments have been proposed
to play an important role in a-syn oligomerization and toxic
conversion.28,61,62 It is possible that progressive accumula-
tion of these a-syn oligomers containing CT fragments
might interfere with axonal transport, resulting in neuritic
dystrophy.
Thus, generation of antibodies that speciﬁcally detect the
aa 122 epitope exposed after calpain-1 digestion in human
diseased brains and in respective animal models are
important tools to understand the underlying pathogenic
processes. Although antibodies against deﬁned a-syn
epitopes that detect different a-syn species already have
been developed,27,28,55,63,64 these antibodies often detect
murine a-syn or cross-react with FL a-syn. By using the aa
122 region of the human a-syn protein, which is a major
cleavage site of calpain-1 and also contains a mismatch
between murine and human a-syn sequence, we were able
to generate an antibody that strongly detects the human
truncated a-syn.
Although extensive biochemical evidence points toward the
afﬁnity of SYN105 binding to calpain cleaved CT a-syn, an
alternative explanation for the lower-molecular-weight band
identiﬁed by the SYN105 antibody is the fact that this band
might represent a splice variant of a-syn. New evidence exists
that both wild-type controls and tg mice expressing human a-
syn under the mThy1-promoter may express splice variants ofajp.amjpathol.org - The American Journal of Pathology
Axonopathy and CT-a-Syn in DLB and Micethe a-syn gene, which are increased in the hippocampal
region.65 However, its speciﬁc molecular weight is identical in
electrophoretic motility assays to the calpain-1 cleaved
recombinant a-syn fragment. In addition, owing to the fact that
hippocampal protein extracts of non-tg mice did not contain
lower-molecular-weight a-syn bands when detecting with the
antibody with epitope localized within amino acid residues 91
to 99,66 it appears unlikely that the detected fragment consists
of neither the a-syn 112 splice variant, that lacks amino acid
residues 41e54 nor the previously (described a-syn 126
variant, which lacks amino acid residue 103e130 owing to
a loss of exon 5.). In addition, Muntane et al,64 albeit using
speciﬁc antibody against the 112 isoform of a-syn, failed to
detect this isoform in human brain, suggesting that this isoform
might not be expressed at the protein level.
The mechanisms governing CT a-syn’s role in selectively
accumulating in axons and presynaptic terminals versus the
cell body or dendrites is not completely clear. One possi-
bility might be that a-synecleaving enzymes such as
calpain-1 might be concentrated in these regions; however,
immunoelectron microscopy studies have shown that
calpain-1 is present both in presynaptic and postsynaptic
regions.67 a-Syn is primarily a presynaptic terminal protein2
that is transported via slow axonal mechanisms,68 suggest-
ing that the cleavage occurs at the axonal site and because of
alterations in axonal transport, the CT fragments accumulate
at the axons. The a-syn CT fragments also may be more
difﬁcult to clear and additionally may promote oligomeri-
zation and further accumulation that might contribute to
axonal transport defects. Previous studies have shown that
both in PD and DLB patients and in primary neuronal
cultures, a-syn interferes with the transport of other synaptic
proteins such as synapsin-I, resulting in synaptic dysfunc-
tion.6,69 Moreover, a recent study in tg mice reported that
a-syn enhances axonal degeneration after peripheral nerve
lesion.70 Thus, growing experimental evidence suggests that
a-syn fragments and aggregates are abundant in synapses
and axons and may interfere with axonal transport.
Our study indicates that neuritic dystrophy is a prominent
feature of the mThy1-a-syn tg model and that CT a-syn
might play an important role in the process of axonal
damage in the tg model as well as in DLB and PD.
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